Shares of Arch Therapeutics Inc (NASDAQ:ARTH) have earned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $2.83.

A number of equities research analysts recently weighed in on ARTH shares. Zacks Investment Research upgraded Arch Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Arch Therapeutics in a research report on Monday, September 18th. Ifs Securities restated an “outperform” rating on shares of Arch Therapeutics in a research report on Tuesday, July 25th. Finally, ValuEngine upgraded Arch Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th.

TRADEMARK VIOLATION WARNING: “Arch Therapeutics Inc (ARTH) Given Consensus Rating of “Buy” by Brokerages” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://theolympiareport.com/2017/10/11/arch-therapeutics-inc-arth-given-consensus-rating-of-buy-by-brokerages.html.

Shares of Arch Therapeutics (NASDAQ ARTH) traded up 0.60% during mid-day trading on Wednesday, reaching $0.79. The company’s stock had a trading volume of 69,854 shares. Arch Therapeutics has a 52-week low of $0.41 and a 52-week high of $0.89. The firm has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.63. The firm’s market cap is $119.11 million.

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.